

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM385280

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
InSite Vision Incorporated		03/01/2016	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Sun Pharma Global FZE		
Street Address:	Executive Suite Y-43		
Internal Address:	P.O. Box 122304		
City:	Sharjah		
State/Country:	UNITED ARAB EMIRATES		
Entity Type:	Limited Liability Company: UNITED ARAB EMIRATES		
PROPERTY NUMBERS Total: 8			
Property Type	Number	Word Mark	
Serial Number:	86288680	DEXASITE	
Serial Number:	86365042	BLESSSED	
Serial Number:	86365047	BLEQCL	
Serial Number:	86365048	BLEQOLITY	
Registration Number:	1769077	DURASITE	
Serial Number:	86678084	BROMDEX	
Serial Number:	86343549		
Serial Number:	86508845	BROMSITE	
CORRESPONDENCE DATA			
Fax Number:	6095149779		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	6097205622		
Email:	general.ip.mailbox@sunpharma.com		
Correspondent Name:	Ranbaxy Inc., a Sun Pharma Company		
Address Line 1:	600 College Road East, Suite 2100		
Address Line 2:	Intellectual Property Dept.		
Address Line 4:	Princeton, NEW JERSEY 08540		
ATTORNEY DOCKET NUMBER:	Sun Pharma Global FZE		
NAME OF SUBMITTER:	Harin Mehta, Director		

OP \$215.00 86288680

SIGNATURE:	/harin mehta/
DATE SIGNED:	05/23/2016
Total Attachments: 13 source=Bill of sale and assignment - InSite to Sun Global - REVISED & EXECUTED#page1.tif source=Bill of sale and assignment - InSite to Sun Global - REVISED & EXECUTED#page2.tif source=Bill of sale and assignment - InSite to Sun Global - REVISED & EXECUTED#page3.tif source=Bill of sale and assignment - InSite to Sun Global - REVISED & EXECUTED#page4.tif source=Bill of sale and assignment - InSite to Sun Global - REVISED & EXECUTED#page5.tif source=Bill of sale and assignment - InSite to Sun Global - REVISED & EXECUTED#page6.tif source=Bill of sale and assignment - InSite to Sun Global - REVISED & EXECUTED#page7.tif source=Bill of sale and assignment - InSite to Sun Global - REVISED & EXECUTED#page8.tif source=Bill of sale and assignment - InSite to Sun Global - REVISED & EXECUTED#page9.tif source=Bill of sale and assignment - InSite to Sun Global - REVISED & EXECUTED#page10.tif source=Bill of sale and assignment - InSite to Sun Global - REVISED & EXECUTED#page11.tif source=Bill of sale and assignment - InSite to Sun Global - REVISED & EXECUTED#page12.tif source=Bill of sale and assignment - InSite to Sun Global - REVISED & EXECUTED#page13.tif	



BILL OF SALE AND ASSIGNMENT

THIS BILL OF SALE AND ASSIGNMENT (the "Agreement") by and between **INSITE VISION INCORPORATED** ("InSite"), a Delaware corporation having an address at 965 Atlantic Avenue, Alameda CA 94501 and **SUN PHARMA GLOBAL FZE**, a Sharjah free zone limited liability establishment having its registered address at Executive Suite Y-43, P. O. Box 122304, Sharjah, United Arab Emirates ("Sun"), is entered into as of March 1, 2016 (the "Closing Date"). InSite and Sun are sometimes referred to herein individually as a "Party" and collectively as the "Parties".

1. Definitions

Each of the capitalized terms used in this Agreement (other than the headings of the Articles and Sections), whether used in singular or plural form, shall have the meaning as set forth below or as designated in places throughout this Agreement.

2. Bill of Sale

In exchange for the Purchase Price, InSite hereby sells, transfers, conveys and delivers to Sun, free and clear of any and all rights of first option, rights of first refusal or similar restriction, encumbrances, claims, mortgages, security interests, charges, restrictions and liens, all of InSite's right, title and interest in and to:

(a) The products and product candidates each of which is commercialized or in development, the accompanying patents, trademarks, copyrights, licenses, regulatory files (including correspondence with regulatory authorities), registrations, applications, approvals, permits, records and reports related to the pharmacological agents listed in (a), the foregoing items being fully described in **SCHEDULE 1**;

(b) all licenses of items mentioned in (a), such licenses and related agreements being listed as **SCHEDULE 2** and appended hereto, and

(c) all other assets related to the products listed in (a) not otherwise herein listed (together with (a) and (b), the "Assets").

InSite hereby covenants that it will, whenever and as often as reasonably required to do so by Sun, execute, acknowledge and deliver any and all such other and further deeds, assignments, transfers, conveyances, confirmations, powers of attorney and any instruments of further assurance, approvals and consents as Sun may reasonably require in order to complete,



insure and perfect the transfer, conveyance and assignment to Sun of all the right, title and interest of InSite in and to the Assets hereby sold, conveyed or assigned, or intended so to be.

3. Purchase Price

The aggregate price to be paid for the Assets shall be \$66,650,000 (sixty-six million six hundred fifty thousand dollars) (the "Purchase Price"). The Purchase Price shall be due and payable by Sun to InSite on the Closing Date, by wire transfer payment as directed by InSite.

4. Indemnity

Sun shall indemnify InSite for all costs and expenses (including but not limited to attorney's fees) incurred in attempt(s) to collect any payments due under this Agreement or to enforce any remedy provided under this Agreement.

5. Assumed Liabilities

All liabilities arising out of the research, clinical studies, development, manufacture, sale or use of the Assets by InSite prior to the Closing Date shall be assumed by Sun. Any judgements, decisions, awards, penalties and amounts owing related to the Assets, if assessed against InSite shall be paid by Sun. Sun shall bear all costs, and shall have the right to direct the defense, of any legal proceedings brought against InSite related to the Assets. InSite shall have the right to refuse any legal settlement agreed by Sun in the name of InSite by (a) indemnifying and holding harmless Sun for such legal proceeding and (b) paying all costs associated with such legal proceeding.

Sun hereby assumes all InSite obligations under the agreements and licenses mentioned in section 2.(b) (such agreements the "Licenses") and hereby indemnifies InSite for any obligations related to the Licenses.

6. Assignment

This Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the consent of the other Party. Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement.

7. Binding Effect

The covenants and agreements set forth herein shall be binding upon, and shall inure to the benefit of, the respective successors and assigns of InSite and Sun.



8. Further Assurances

InSite agrees that, from time to time after the Closing Date, it will, upon the reasonable request of Sun, take all such action and execute and deliver all such documents, instruments and conveyances which may be reasonably necessary or desirable to carry out the provisions of this Agreement.

9. Governing Law

This Agreement shall be governed by and construed in accordance with the laws of the State of California, without regard to conflict of laws principles.

[the next page is the signature page]



IN WITNESS WHEREOF, the Parties, through their authorized officers, have duly executed this Agreement as of the date first written above.

SUN PHARMA GLOBAL FZE

INSITE VISION INCORPORATED

By: Harin Mehta
Name: Harin Mehta
Title: Director

By: Lyle Bowman
Name: Lyle Bowman
Title: Vice President, Development



SCHEDULE 1

Trademarks

Client-Matter No.	Country	Trademark	Application No.	Application Date	Registration No.	Registration Date
075538-0261	Canada	DURASITE	716434	11/6/1992	TMA432299	8/26/1994
075538-0340	European Community	DURASITE	005961701	6/1/2007	005961701	6/1/2007
075538-0465	European Community	BROMSITE	013084561	7/15/2014	013084561	12/9/2014
075538-0341	Japan	DURASITE	055438/2007	6/1/2007	5123917	3/28/2008
075538-0252	Republic of Korea	AQUASITE (IN KOREAN CHARACTERS)	40-2000-0039026	8/12/2000	511297	1/28/2002
075538-0253	Republic of Korea	DURASITE (IN KOREAN CHARACTERS)	40-2000-0039027	8/12/2000	511296	1/28/2002
075538-0249	Republic of Korea	DURASITE	50-2010-5926	8/6/1999	473727	7/20/2000
075538-0462	United States of America	DEXASITE	86/288680	5/22/2014		
075538-0466	United States of America	BLESSED	86/365042	8/13/2014		
075538-0467	United States of America	BLEQCL	86/365047	8/13/2014		
075538-0468	United States of America	BLEQOLITY	86/365048	8/13/2014		
075538-0264	United States of America	DURASITE	74/010027	12/12/1989	1769077	5/4/1993
075538-0477	United States of America	BROMDEX	86/678084	6/29/2015		
075538-0464	United States of America	DURASITE (AND DESIGN)	86/343549	7/21/2014		
075538-0463	United States of America	BROMSITE	86/508845	1/20/2015		



Patents

Matter No.	Application No./Patent (Grant) No.	Patent Title	Filing Date/Issue (Grant)Date	Country
075538-0011 (co-owned)	7758553	DROP DISPENSER FOR THE DELIVERY OF UNIFORM DROPLETS OF VISCOUS LIQUIDS	20-Jul-10	United States of America
075538-0013 (co-owned)	D543118	DROP DISPENSER	22-May-07	United States of America
075538-0015	6309630	NON-STEROIDAL ANTI-INFLAMMATORY OPHTHALMIC SUSPENSIONS	30-Oct-01	United States of America
075538-0058	6265444	OPHTHALMIC COMPOSITIONS	24-Jul-01	United States of America
075538-0061	503063	SUSTAINED RELEASE OPHTHALMIC COMPOSITIONS CONTAINING WATER SOLUBLE MEDICAMENTS	5-Aug-02	New Zealand
075538-0063	6378526	METHODS OF OPHTHALMIC ADMINISTRATION	30-Apr-02	United States of America
075538-0069	6397849	METHODS OF OPHTHALMIC ADMINISTRATION	4-Jun-02	United States of America
075538-0070	6309374	INJECTION APPARATUS AND METHOD OF USING SAME	30-Oct-01	United States of America
075538-0077	6299603	INJECTION APPARATUS AND METHOD OF USING SAME	9-Oct-01	United States of America
075538-0079	7141607	METHODS AND COMPOSITIONS FOR TREATING AND INHIBITING RETINAL NEOVASCULARIZATION	28-Nov-06	United States of America
075538-0082	2001/8955	METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING POSTERIOR SEGMENT OPHTHALMIC DISORDERS	29-Jan-03	South Africa
075538-0227	1261317	METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING POSTERIOR SEGMENT OPHTHALMIC DISORDERS	10-Oct-07	European Patent Office
075538-0227/DE	60130872.7	METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING POSTERIOR SEGMENT OPHTHALMIC DISORDERS	10-Oct-07	Germany
075538-0227/FR	1261317	METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING POSTERIOR SEGMENT OPHTHALMIC DISORDERS	10-Oct-07	France
075538-0227/GB	1261317	METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING POSTERIOR SEGMENT OPHTHALMIC DISORDERS	10-Oct-07	United Kingdom
075538-0227/IT	1261317	METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING POSTERIOR SEGMENT OPHTHALMIC DISORDERS	10-Oct-07	Italy



Matter No.	Application No./Patent (Grant) No.	Patent Title	Filing Date/issue (Grant)Date	Country
075538-0228	785285	METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING POSTERIOR SEGMENT OPHTHALMIC DISORDERS	5-Apr-07	Australia
075538-0269	772228	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	20-Aug-04	Australia
075538-0271	1165058	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	25-May-05	European Patent Office
075538-0271/AT	1165058	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	25-May-05	Austria
075538-0271/BE	1165058	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	25-May-05	Belgium
075538-0271/CH	1165058	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	25-May-05	Switzerland
075538-0271/CY	CY05/1101022	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	25-May-05	Cyprus
075538-0271/DE	1165058	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	25-May-05	Germany
075538-0271/DK	1165058	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	25-May-05	Denmark
075538-0271/ES	1165058	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	25-May-05	Spain
075538-0271/FI	1165058	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	25-May-05	Finland
075538-0271/FR	1165058	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	25-May-05	France
075538-0271/GB	1165058	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	25-May-05	United Kingdom
075538-0271/GR	1165058	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	25-May-05	Greece
075538-0271/IE	1165058	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	25-May-05	Ireland
075538-0271/IT	1165058	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	25-May-05	Italy
075538-0271/LU	1165058	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	25-May-05	Luxembourg
075538-0271/MC	1165058	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	25-May-05	Monaco
075538-0271/NL	1165058	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	25-May-05	Netherlands
075538-0271/PT	1165058	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	25-May-05	Portugal



Matter No.	Application No./Patent (Grant) No.	Patent Title	Filing Date/Issue (Grant)Date	Country
075538-0271/SE	1165058	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	25-May-05	Sweden
075538-0272	05011127.7	AZALIDE ANTIBIOTICS FOR THE TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	27-Mar-00	European Patent Office
075538-0273	4904621	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	20-Jan-12	Japan
075538-0274	10-0701721	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	23-Mar-07	Republic of Korea
075538-0275	226992	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	30-Mar-05	Mexico
075538-0276	252105	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	3-Dec-07	Mexico
075538-0277	2001/7454	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	27-Nov-02	South Africa
075538-0278	514378	TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	29-Mar-04	New Zealand
075538-0280	HK1041642	AZALIDE ANTIBIOTICS FOR THE TOPICAL TREATMENT OR PREVENTION OF OCULAR INFECTIONS	23-Dec-05	Hong Kong
075538-0281	780671	TOPICAL TREATMENT FOR PREVENTION	28-Jul-05	Australia
075538-0282	2005202889	TOPICAL TREATMENT FOR PREVENTION OF OCULAR INFECTIONS	20-Dec-07	Australia
075538-0283	2384717	TOPICAL TREATMENT FOR PREVENTION OF OCULAR INFECTIONS	27-Jul-10	Canada
075538-0284	1212058	TOPICAL TREATMENT FOR PREVENTION OF OCULAR INFECTIONS	23-Aug-06	European Patent Office
075538-0284/BE	1212058	TOPICAL TREATMENT FOR PREVENTION OF OCULAR INFECTIONS	23-Aug-06	Belgium
075538-0284/DE	1212058	TOPICAL TREATMENT FOR PREVENTION OF OCULAR INFECTIONS	23-Aug-06	Germany
075538-0284/FR	1212058	TOPICAL TREATMENT FOR PREVENTION OF OCULAR INFECTIONS	23-Aug-06	France
075538-0284/GB	1212058	TOPICAL TREATMENT FOR PREVENTION OF OCULAR INFECTIONS	23-Aug-06	United Kingdom
075538-0287	20021957	TOPICAL TREATMENT FOR PREVENTION	28-Mar-03	South Africa
075538-0315	1309699	CAP	10-Aug-07	Japan
075538-0316	117644	CAP	17-Jan-08	Canada
075538-0317	311459	CAP	23-Nov-06	Australia
075538-0318	ZL2006301457 81.X	CAP	2-Jul-08	China



Matter No.	Application No./Patent (Grant) No.	Patent Title	Filing Date/Issue (Grant)Date	Country
075538-0319	408189	DROP DISPENSER	3-Apr-06	New Zealand
075538-0320	30-0454860	CAP	27-Jun-07	Republic of Korea
075538-0322	000597547-0001	CAP	14-Nov-06	European Community
075538-0323	1318085	DROP DISPENSER FOR A PACKAGING CONTAINER	22-Nov-07	Japan
075538-0324	117642	DROP DISPENSER	28-Sep-07	Canada
075538-0325	311237	DROP DISPENSER	6-Jul-07	Australia
075538-0326	ZL200630145780.5	DROP DISPENSER	23-Apr-08	China
075538-0327	408190	DROP DISPENSER	3-Apr-06	New Zealand
075538-0328	454861	DROP DISPENSER	27-Jun-07	Republic of Korea
075538-0330	000597554-0001	DROP DISPENSER	29-Sep-06	European Community
075538-0338/EP-A002	1938799	METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING POSTERIOR SEGMENT OPHTHALMIC DISORDERS	8-May-13	European Patent Office
075538-0365	1490002	CONCENTRATED AQUEOUS AZALIDE FORMULATIONS	1-Jul-15	Taiwan
075538-0369 (co-owned)	D603525	CHARGING FIXTURE WITH VALVES	3-Nov-09	United States of America
075538-0372	2645754	DROP DISPENSER FOR THE DELIVERY OF UNIFORM DROPLETS OF VISCOUS LIQUIDS	21-Jul-15	Canada
075538-0374/AT-A006	AT-E0549058	DROP DISPENSER FOR THE DELIVERY OF UNIFORM DROPLETS OF VISCOUS LIQUIDS	14-Mar-12	Austria
075538-0374/BE-A006	2007469	DROP DISPENSER FOR THE DELIVERY OF UNIFORM DROPLETS OF VISCOUS LIQUIDS	14-Mar-12	Belgium
075538-0374/CH-A006	2007469	DROP DISPENSER FOR THE DELIVERY OF UNIFORM DROPLETS OF VISCOUS LIQUIDS	14-Mar-12	Switzerland
075538-0374/DE-A006	602007021312.6	DROP DISPENSER FOR THE DELIVERY OF UNIFORM DROPLETS OF VISCOUS LIQUIDS	14-Mar-12	Germany
075538-0374/DK-A006	2007469	DROP DISPENSER FOR THE DELIVERY OF UNIFORM DROPLETS OF VISCOUS LIQUIDS	14-Mar-12	Denmark
075538-0374/EP-A006	2007469	DROP DISPENSER FOR THE DELIVERY OF UNIFORM DROPLETS OF VISCOUS LIQUIDS	14-Mar-12	European Patent Office
075538-0374/ES-A006	2007469	DROP DISPENSER FOR THE DELIVERY OF UNIFORM DROPLETS OF VISCOUS LIQUIDS	14-Mar-12	Spain
075538-0374/FI-A006	2007469	DROP DISPENSER FOR THE DELIVERY OF UNIFORM DROPLETS OF VISCOUS LIQUIDS	14-Mar-12	Finland
075538-0374/FR-A006	2007469	DROP DISPENSER FOR THE DELIVERY OF UNIFORM DROPLETS OF VISCOUS LIQUIDS	14-Mar-12	France
075538-0374/GB-A006	2007469	DROP DISPENSER FOR THE DELIVERY OF UNIFORM DROPLETS OF VISCOUS LIQUIDS	14-Mar-12	United Kingdom

Matter No.	Application No./Patent (Grant) No.	Patent Title	Filing Date/Issue (Grant)Date	Country
075538-0374/IE-A006	2007469	DROP DISPENSER FOR THE DELIVERY OF UNIFORM DROPLETS OF VISCOUS LIQUIDS	14-Mar-12	Ireland
075538-0374/IT-A006	2007469	DROP DISPENSER FOR THE DELIVERY OF UNIFORM DROPLETS OF VISCOUS LIQUIDS	14-Mar-12	Italy
075538-0374/NL-A006	2007469	DROP DISPENSER FOR THE DELIVERY OF UNIFORM DROPLETS OF VISCOUS LIQUIDS	14-Mar-12	Netherlands
075538-0374/PT-A006	2007469	DROP DISPENSER FOR THE DELIVERY OF UNIFORM DROPLETS OF VISCOUS LIQUIDS	14-Mar-12	Portugal
075538-0374/SE-A006	2007469	DROP DISPENSER FOR THE DELIVERY OF UNIFORM DROPLETS OF VISCOUS LIQUIDS	14-Mar-12	Sweden
075538-0382	8501800	CONTROLLED-RELEASE OPHTHALMIC VEHICLES	6-Aug-13	United States of America
075538-0383	12/399729	METHODS FOR TREATING OCULAR INFLAMMATORY DISEASES	6-Mar-09	United States of America
075538-0384	8778999	NON-STEROIDAL ANTI-INFLAMMATORY OPHTHALMIC COMPOSITIONS	15-Jul-14	United States of America
075538-0386	8695850	TIP ARRANGEMENT FOR A DROPPER BOTTLE	15-Apr-14	United States of America
075538-0389	130313	CHARGING FIXTURE	14-Jan-10	Canada
075538-0391	326433	CHARGING FIXTURE	16-Jun-09	Australia
075538-0392	412177	CHARGING FIXTURE	22-Apr-10	New Zealand
075538-0393	30-0563889	CHARGING FIXTURE	7-Jun-10	Republic of Korea
075538-0394	222382	CHARGING FIXTURE	10-Oct-08	India
075538-0395	001119879-0001	CHARGING FIXTURE	3-Jul-09	European Community
075538-0395-0002	001119879-0002	CHARGING FIXTURE	3-Jul-09	European Community
075538-0396	222383	CHARGING FIXTURE	26-Nov-09	India
075538-0397	30-0563888	CHARGING FIXTURE	7-Jun-10	Republic of Korea
075538-0398	326649	CHARGING FIXTURE	6-Jul-09	Australia
075538-0410	08796298.1	CONCENTRATED AQUEOUS AZALIDE FORMULATIONS	30-Apr-10	European Patent Office
075538-0411	10-2010-7009823	CONCENTRATED AQUEOUS AZALIDE FORMULATIONS	3-May-10	Republic of Korea
075538-0425	13/188730	COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE ALLERGIES	22-Jul-11	United States of America
075538-0427	10749383.5	CONTROLLED-RELEASE OPHTHALMIC VEHICLES	19-Sep-11	European Patent Office
075538-0428	2753847	METHODS FOR TREATING OCULAR INFLAMMATORY DISEASES	26-Aug-11	Canada
075538-0429	10749281.1	METHODS FOR TREATING OCULAR INFLAMMATORY DISEASES	19-Sep-11	European Patent Office



Matter No.	Application No./Patent (Grant) No.	Patent Title	Filing Date/Issue (Grant)Date	Country
075538-0430	2753947	NON-STEROIDAL ANTI-INFLAMMATORY OPHTHALMIC COMPOSITIONS	26-Aug-11	Canada
075538-0431	10749380.1	NON-STEROIDAL ANTI-INFLAMMATORY OPHTHALMIC COMPOSITIONS	19-Sep-11	European Patent Office
075538-0432	2403470	DROPPER BOTTLE ASSEMBLY AND METHOD FOR OPENING IT	21-Jan-15	European Patent Office
075538-0435	13/345087	METHODS AND KITS FOR EXTENDING CONTACT LENS USE	6-Jan-12	United States of America
075538-0446	12803892.4	METHODS OF TREATING RECURRENT MEIBOMIAN GLANDS DISORDER AND THEREBY DECREASING THE FREQUENCY OF RECURRENCE	9-Jan-14	European Patent Office
075538-0447	2840626	METHODS OF TREATING RECURRENT MEIBOMIAN GLANDS DISORDER AND THEREBY DECREASING THE FREQUENCY OF RECURRENCE	24-Dec-13	Canada
075538-0448	2014-519145	METHODS OF TREATING RECURRENT BLEPHARITIS, BLEPHAROCONJUNCTIVITIS AND/OR MEIBOMIAN GLANDS DISORDER AND THEREBY DECREASING THE FREQUENCY OF RECURRENCE	27-Dec-13	Japan
075538-0449	10-2014-7002457	METHODS OF TREATING RECURRENT MEIBOMIAN GLANDS DISORDER AND THEREBY DECREASING THE FREQUENCY OF RECURRENCE	28-Jan-14	Republic of Korea
075538-0450	14/149743	METHODS FOR TREATMENT OF POSTOPERATIVE INFLAMMATION WITH REDUCED INTRAOCULAR PRESSURE	7-Jan-14	United States of America
075538-0451	2840727	COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE ALLERGIES	30-Dec-13	Canada
075538-0452	12817001.6	COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE ALLERGIES	13-Feb-14	European Patent Office
075538-0453	2014-521778	COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE ALLERGIES	17-Jan-14	Japan
075538-0457	PCT/US2014/022084	CONCENTRATED AQUEOUS AZALIDE FORMULATIONS	7-Mar-14	Patent Cooperation Treaty
075538-0458	2861825	METHODS AND KITS FOR EXTENDING CONTACT LENS USE	26-Jun-14	Canada
075538-0459	13733573.3	METHODS AND KITS FOR EXTENDING CONTACT LENS USE	3-Jul-14	European Patent Office
075538-0460	2014-551342	METHODS AND KITS FOR EXTENDING CONTACT LENS USE	25-Jun-14	Japan
075538-0469	PCT/US2014/071132	METHODS FOR TREATMENT OF POSTOPERATIVE INFLAMMATION WITH REDUCED INTRAOCULAR PRESSURE	18-Dec-14	Patent Cooperation Treaty



Matter No.	Application No./Patent (Grant) No.	Patent Title	Filing Date/Issue (Grant)Date	Country
075538-0470	2403470	TIP ARRANGEMENT FOR A DROPPER BOTTLE	21-Jan-15	France
075538-0471	602010021969 .0	TIP ARRANGEMENT FOR A DROPPER BOTTLE	21-Jan-15	Germany
075538-0472	2403470	TIP ARRANGEMENT FOR A DROPPER BOTTLE	21-Jan-15	Italy
075538-0473	2403470	TIP ARRANGEMENT FOR A DROPPER BOTTLE	21-Jan-15	Sweden
075538-0474	2403470	TIP ARRANGEMENT FOR A DROPPER BOTTLE	21-Jan-15	United Kingdom
075538-0478	14/846446	OPHTHALMIC FORMULATIONS OF MYCOPHENOLIC ACID	4-Sep-15	United States of America
075538-0481	10-2015-7025923	CONCENTRATED AQUEOUS AZALIDE FORMULATIONS	21-Sep-15	Republic of Korea
075538-0482	NOT ASSIGNED	CONCENTRATED AQUEOUS AZALIDE FORMULATIONS	10-Sep-15	Japan
075538-0483	2698383	CONCENTRATED AQUEOUS AZALIDE FORMULATIONS	7-Mar-14	European Patent Office
075538-0484	201480018949 .2	CONCENTRATED AQUEOUS AZALIDE FORMULATIONS	28-Sep-15	China
075538-0486	16000070.9	CONTROLLED-RELEASE OPHTHALMIC VEHICLES	12-Jan-16	European Patent Office



SCHEDULE 2 – LIST OF LICENSES

Exclusive License Agreement dated as of February 15, 2007 between Pfizer Products, Inc. and InSite Vision Incorporated, with the exception of Licensed Patents in the U.S. and Canada and their related rights and obligations

License Agreement dated as of March 31, 2014 between Senju Pharmaceutical Co., Ltd. and InSite Vision Incorporated

Exclusive Licence and Development Agreement dated January 29, 2015 between Nicox S.A. and InSite Vision Incorporated

Royalty Purchase Agreement dated as of April 2, 2013 between SWK Funding LLC and Bess Royalty, L.P. and InSite Vision Incorporated

InSite Authorized Distributor Agreement dated December 17, 2007 between Shin Poong Pharm Co., Ltd. and InSite Vision Incorporated

ISV-403 Asset Purchase Agreement dated December 19, 2003 between Bausch & Lomb Incorporated and InSite Vision Incorporated.